Penumbra (PEN) Competitors $239.63 -0.76 (-0.32%) Closing price 03:59 PM EasternExtended Trading$240.00 +0.38 (+0.16%) As of 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock PEN vs. LNTH, ITGR, GEHC, PHG, ZBH, SNN, SOLV, STVN, GKOS, and BLCOShould you be buying Penumbra stock or one of its competitors? The main competitors of Penumbra include Lantheus (LNTH), Integer (ITGR), GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Smith & Nephew SNATS (SNN), Solventum (SOLV), Stevanato Group (STVN), Glaukos (GKOS), and Bausch + Lomb (BLCO). These companies are all part of the "medical" sector. Penumbra vs. Its Competitors Lantheus Integer GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Smith & Nephew SNATS Solventum Stevanato Group Glaukos Bausch + Lomb Lantheus (NASDAQ:LNTH) and Penumbra (NYSE:PEN) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, institutional ownership, media sentiment, profitability, dividends, risk and analyst recommendations. Is LNTH or PEN more profitable? Lantheus has a net margin of 16.55% compared to Penumbra's net margin of 11.54%. Lantheus' return on equity of 36.99% beat Penumbra's return on equity.Company Net Margins Return on Equity Return on Assets Lantheus16.55% 36.99% 20.55% Penumbra 11.54%11.55%8.76% Do analysts rate LNTH or PEN? Lantheus currently has a consensus price target of $131.20, suggesting a potential upside of 80.64%. Penumbra has a consensus price target of $300.47, suggesting a potential upside of 25.39%. Given Lantheus' higher probable upside, equities analysts plainly believe Lantheus is more favorable than Penumbra.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantheus 0 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.83Penumbra 0 Sell rating(s) 3 Hold rating(s) 13 Buy rating(s) 2 Strong Buy rating(s) 2.94 Do insiders and institutionals hold more shares of LNTH or PEN? 99.1% of Lantheus shares are held by institutional investors. Comparatively, 88.9% of Penumbra shares are held by institutional investors. 2.0% of Lantheus shares are held by insiders. Comparatively, 5.0% of Penumbra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor LNTH or PEN? In the previous week, Penumbra had 22 more articles in the media than Lantheus. MarketBeat recorded 46 mentions for Penumbra and 24 mentions for Lantheus. Lantheus' average media sentiment score of 0.94 beat Penumbra's score of 0.56 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 15 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Penumbra 15 Very Positive mention(s) 6 Positive mention(s) 8 Neutral mention(s) 2 Negative mention(s) 1 Very Negative mention(s) Positive Which has higher valuation & earnings, LNTH or PEN? Lantheus has higher revenue and earnings than Penumbra. Lantheus is trading at a lower price-to-earnings ratio than Penumbra, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioLantheus$1.53B3.28$312.44M$3.5220.63Penumbra$1.28B7.30$14.01M$3.7663.73 Which has more risk & volatility, LNTH or PEN? Lantheus has a beta of 0.14, indicating that its stock price is 86% less volatile than the S&P 500. Comparatively, Penumbra has a beta of 0.4, indicating that its stock price is 60% less volatile than the S&P 500. SummaryPenumbra beats Lantheus on 9 of the 17 factors compared between the two stocks. Get Penumbra News Delivered to You Automatically Sign up to receive the latest news and ratings for PEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding PEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PEN vs. The Competition Export to ExcelMetricPenumbraMED INSTRUMENTS IndustryMedical SectorNYSE ExchangeMarket Cap$9.35B$6.74B$5.54B$20.58BDividend YieldN/A1.31%4.73%3.69%P/E Ratio63.7321.1428.9629.45Price / Sales7.3053.67374.6974.44Price / Cash84.1920.8324.4817.52Price / Book7.994.708.644.62Net Income$14.01M$176.39M$3.24B$993.83M7 Day Performance5.44%-1.82%0.39%-0.87%1 Month Performance-4.35%-3.03%8.20%0.36%1 Year Performance34.96%14.32%30.15%16.75% Penumbra Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PENPenumbra4.8631 of 5 stars$239.63-0.3%$300.47+25.4%+37.1%$9.35B$1.28B63.734,500Earnings ReportAnalyst DowngradeLNTHLantheus4.6802 of 5 stars$72.41-0.7%$131.20+81.2%-26.8%$5.01B$1.54B20.57700News CoverageUpcoming EarningsITGRInteger3.3923 of 5 stars$108.02-0.5%$140.25+29.8%-4.3%$3.77B$1.79B47.5911,000GEHCGE HealthCare Technologies4.335 of 5 stars$77.74+0.2%$88.55+13.9%-15.3%$35.60B$19.67B16.3753,000Positive NewsEarnings ReportPHGKoninklijke Philips3.6656 of 5 stars$25.65-1.9%N/A-6.2%$24.70B$19.50B59.6566,678Earnings ReportAnalyst DowngradeZBHZimmer Biomet4.6528 of 5 stars$95.94-1.7%$111.39+16.1%-16.2%$18.98B$7.70B21.2317,000News CoveragePositive NewsUpcoming EarningsSNNSmith & Nephew SNATS3.0935 of 5 stars$31.19-1.5%$28.00-10.2%+1.1%$13.66B$5.81B14.4417,349News CoveragePositive NewsGap UpSOLVSolventum1.3692 of 5 stars$73.80-1.3%$84.38+14.3%+27.8%$12.77B$8.31B34.1722,000News CoveragePositive NewsUpcoming EarningsSTVNStevanato Group2.4189 of 5 stars€25.77-2.8%N/A+33.2%€7.80B€1.19B50.535,521News CoverageGKOSGlaukos3.9868 of 5 stars$94.80+0.5%$134.67+42.1%-24.6%$5.42B$383.48M-40.00780Earnings ReportBLCOBausch + Lomb2.0536 of 5 stars$14.47+1.0%$15.45+6.8%-15.7%$5.12B$4.79B-14.0513,500Earnings Report Related Companies and Tools Related Companies Lantheus Competitors Integer Competitors GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Smith & Nephew SNATS Competitors Solventum Competitors Stevanato Group Competitors Glaukos Competitors Bausch + Lomb Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:PEN) was last updated on 8/5/2025 by MarketBeat.com Staff From Our PartnersMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredOne stock to replace NvidiaI'm a Futurist: Here are 3 stocks better than Nvidia Nvidia's own customers could soon become fierce compet...InvestorPlace | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Penumbra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Penumbra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.